Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CYRX with free AI briefings, catalyst countdowns, and dilution alerts.

CYRX · Cryoport, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$393.1M Cash on Hand
CF+ Cash Runway
Follow CYRX by email Get an email when CYRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CYRX, unsubscribe in one click. Privacy

📣 What CYRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

CYRX holds $393.1M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CYRX files for a raise →

👥 Who Owns CYRX

Insiders 3.5% Institutions (259 holders) 92.6% Public and other holders 3.9%
HolderTypeShares% of sharesAs of
Jerrell Shelton
President, CEO, Director · +492,901 options
Insider 1,201,814 2.37% 2026-08-11
Robert Stefanovich
Chief Financial Officer · +82,240 options
Insider 109,850 0.22% 2026-06-04
Edward J Zecchini
Chief Digital and Tech Officer · +63,965 options
Insider 109,719 0.22% 2026-06-10
Mark W Sawicki
Chief Scientific Officer · +68,534 options
Insider 92,356 0.18% 2026-11-10
Daniel M Hancock
Director · +77,724 options
Insider 69,052 0.14% 2026-11-09
Linda Baddour
Director · +57,175 options
Insider 68,099 0.13% 2026-06-05
Ramkumar Mandalam
Director · +57,175 options
Insider 67,894 0.13% 2026-06-05
Robert J Hariri
Director · +57,175 options
Insider 61,625 0.12% 2026-06-05

Share count 50,700,429 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CYRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CYRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.